Literature DB >> 2170253

Pharmacology of noradrenaline and neuropeptide tyrosine (NPY)-mediated sympathetic cotransmission.

J M Lundberg1, A Franco-Cereceda, A Hemsén, J S Lacroix, J Pernow.   

Abstract

Pharmacological and physiological aspects for neuropeptide Y (NPY) and noradrenaline (NA) cotransmission have been studied in the peripheral sympathetic nervous control of blood vessels, heart, spleen and vas deferens. NPY coexists with NA in large dense cored vesicles and is released compared to NA mainly upon high frequency stimulation or strong reflex sympathetic activation. NPY release is inhibited via prejunctional alpha-2 adrenoceptors and adenosine receptors but facilitated by angiotensin II or beta-receptor activation. NPY exerts prejunctional inhibitory actions on both NA and NPY release, enhances the vasoconstrictor effect of NA and evokes potent, long-lasting vasoconstriction. Specific receptor mechanisms for NPY exist at both the pre- and postjunctional levels; a large amidated C-terminal portion of NPY is necessary for receptor binding, inhibition of cyclic AMP formation and vasoconstrictor effects. Denervation results in supersensitivity for both NA and NPY-evoked vasoconstriction. Reserpine pretreatment is associated with depletion of NA as well as NPY; the effect on NPY is entirely dependent on an intact nerve activity. Reserpine treatment combined with preganglionic denervation depletes NA by 99% while NPY levels are maintained intact. The characteristic appearance of the nerve stimulation evoked vasoconstrictor response with a high correlation to NPY outflow after reserpine treatment, suggests that NPY may be involved as a transmitter in a variety of vascular beds. NPY-synthesis in ganglia seems to be regulated by nicotinic receptor activity; secondary stimulation by eg reserpine stimulates and nicotine antagonists decrease NPY-synthesis. Many classical pharmacological agents including guanethidine, clonidine, yohimbine, angiotensin II, nicotine and desipramine influence NPY release. A complex interplay therefore seems to occur at both the pre- and postjunctional levels of transmission for the classical transmitter NA and the coexisting peptide NPY, creating a great diversity of chemical signalling potential.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170253     DOI: 10.1111/j.1472-8206.1990.tb00692.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  21 in total

Review 1.  Role of the sympathetic nervous system in chronic joint pain and inflammation.

Authors:  B L Kidd; S Cruwys; P I Mapp; D R Blake
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

Review 2.  NPY and stress 30 years later: the peripheral view.

Authors:  Dalay Hirsch; Zofia Zukowska
Journal:  Cell Mol Neurobiol       Date:  2012-01-24       Impact factor: 5.046

3.  Maternal low-protein diet up-regulates the neuropeptide Y system in visceral fat and leads to abdominal obesity and glucose intolerance in a sex- and time-specific manner.

Authors:  Ruijun Han; Aiyun Li; Lijun Li; Joanna B Kitlinska; Zofia Zukowska
Journal:  FASEB J       Date:  2012-04-25       Impact factor: 5.191

4.  Changes in plasma catecholamine and neuropeptide Y levels after sympathetic activation in dogs.

Authors:  M F Poncet; C Damase-Michel; G Tavernier; M A Tran; M Berlan; J L Montastruc; P Montastruc
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

5.  Impaired increases in skin sympathetic nerve activity contribute to age-related decrements in reflex cutaneous vasoconstriction.

Authors:  Jody L Greaney; Anna E Stanhewicz; W Larry Kenney; Lacy M Alexander
Journal:  J Physiol       Date:  2015-03-24       Impact factor: 5.182

6.  Neuropeptides in the internal anal sphincter in neurogenic faecal incontinence.

Authors:  C T Speakman; C H Hoyle; M A Kamm; M M Henry; R J Nicholls; G Burnstock
Journal:  Int J Colorectal Dis       Date:  1993-12       Impact factor: 2.571

7.  Effect of neuropeptide Y on adrenergic and non-adrenergic, non-cholinergic responses in the rat anococcygeus muscle.

Authors:  E Vila; A Tabernero; F Fernandes; M Salaices
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

8.  Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.

Authors:  J M Lundberg; A Modin
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

9.  Altered neurotransmitter control of reflex vasoconstriction in aged human skin.

Authors:  Caitlin S Thompson; W Larry Kenney
Journal:  J Physiol       Date:  2004-06-04       Impact factor: 5.182

10.  Modulation by neuropeptide Y of parasympathetic nerve-evoked nasal vasodilatation via Y2 prejunctional receptor.

Authors:  J S Lacroix; L G Ulman; E K Potter
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.